title: [Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer].
abstract: The procedure guideline for radioiodine ((131)I) therapy and (131)I whole-body scintigraphy of differentiated thyroid cancer in paediatric patients is the counterpart to the procedure guidelines (version 3) for adult patients and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Characteristics of thyroid cancer in children are the higher aggressiveness of papillary thyroid cancer, the higher frequency of extrathyroidal extension and of disseminated pulmonary metastases as well as the high risk of local recurrences. Radioiodine therapy is generally recommended in children, the (131)I activity depends on the children's body weight. Radioiodine ablation in children with small papillary cancer (< or =1 cm) should be considered. TSH stimulation is reached two weeks (children) or three weeks (adolescents) after withdrawal of thyroid hormones. Anti-emetic drugs are highly recommended. CT of the chest and examination of pulmonary function are clearly indicated if there is any suspicion on metastases. 3-6 months after (131)I ablation, the (131)I whole-body scintigraphy is highly recommended as lymph node metastases are frequently detected in paediatric patients. Follow-up care should be arranged in shorter intervals than in adults to test the compliance and to adapt dosage of thyroid hormones to the children's body weight. Reference values of fT3 are higher in children than in adults. Evidence is insufficient to describe in which constellation the TSH may be kept within the low normal level. Therefore, TSH suppression is generally recommended.
authors.affiliation: Kliniken und Polikliniken für Nuklearmedizin, Universitätsklinika Münster, Albert-Schweitzer-Str. 33, 48129 Münster. franziu@uni-muenster.de
authors.forename: C
authors.initials: C
authors.lastname: Franzius
authors.forename: M
authors.initials: M
authors.lastname: Dietlein
authors.forename: M
authors.initials: M
authors.lastname: Biermann
authors.forename: M
authors.initials: M
authors.lastname: Frühwald
authors.forename: T
authors.initials: T
authors.lastname: Linden
authors.forename: P
authors.initials: P
authors.lastname: Bucsky
authors.forename: C
authors.initials: C
authors.lastname: Reiners
authors.forename: O
authors.initials: O
authors.lastname: Schober
mesh_terms: D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000592:standards; D017410:Practice Guidelines as Topic; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D013963:Thyroid Hormones / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D051598:Whole Body Imaging / Q000379:methods* / Q000592:standards
chemical_list: D007457:Iodine Radioisotopes; D013963:Thyroid Hormones